Therapy Areas: Inflammatory Diseases
EpiEndo Commences LPS Challenge Trial for Lead Candidate EP395
26 September 2022 - - Iceland-based clinical-stage biopharmaceutical company EpiEndo Pharmaceuticals has received regulatory and ethics approval to commence a Lipopolysaccharide challenge clinical tri...
Alpine Immune Sciences to Host R and D Day
26 September 2022 - - US-based clinical-stage immunotherapy company Alpine Immune Sciences, Inc. (NASDAQ: ALPN) will host an R and D Day featuring clinical data presentations on ALPN-303, a potentiall...
EIP Pharma Publishes Translational Data of Preclinical and Phase 2a Results for Neflamapimod in Dementia with Lewy Bodies: Nature Communications
23 September 2022 - - An article in Nature Communications shows translational results from preclinical animal models to an exploratory, placebo-controlled clinical trial of neflama...
AstraZeneca's Ultomiris approved in EU for gMG
23 September 2022 - Pharmaceutical company AstraZeneca plc (STO:AZN) (LON:AZN) (Nasdaq:AZN) announced on Friday that Ultomiris (ravulizumab) has been approved by European regulators as an add-on to st...
People Science collaborates with Sen-Jam Pharmaceutical
23 September 2022 - People Science, a US-based direct-to-consumer scientific research company providing a scaled R&D platform for alternative medicines, and Sen-Jam Pharmaceutical, a US-based drug...
Immunis Initiates Patient Enrollment for Muscle Atrophy Phase 1/2a Clinical Trial
22 September 2022 - - US-based biotechnology company Immunis Inc has initiated patient enrollment for their Phase 1/2a clinical trial to assess Immunis' immunomodulatory secretome produ...